This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Agrylin

Shire Pharmaceuticals Group PLC

Drug Names(s): anagrelide, Xagrid (EU), KRN654, SPD422

Description: Agrylin reduces platelet count by as yet an unknown mechanism. Studies have shown that it reduces megakaryocyte development.

Deal Structure: In September 2010, Swedish Orphan Biovitrum announced that they will discontinue their marketing, distribution and medical support of Xagrid, Fosrenol, and Equasym in the Nordic countries when the various distribution contracts with Shire expire during 2011.

Abbvie and Shire
In July 2014, AbbVie and Shire announced that they have reached agreement on the terms of a recommended combination of Shire with AbbVie.

In October 2014, AbbVie and Shire have agreed to terminate their proposed merger following the decision by AbbVies Board to withdraw support for the proposed transaction. The Companys decision was based upon its assessment of the September 22, 2014 notice issued by the U.S. Department of Treasury, which re-interpreted longstanding tax principles in a uniquely selective manner designed specifically to destroy the financial benefits of these types of transactions.


Agrylin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug